Loading
Latest filing published 30 Jul 2025 for Lexaria Bioscience Corp., €3,923.
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
William Edward McKechnie discloses dealings in 2 companies, chiefly Lexaria Bioscience Corp. and Lexaria Corp. We count 13 filings; the first trade dates from 16 September 2015 and the latest from 29 July 2025.
In open-market terms, that means 2 purchases worth €21k on one side and 3 sales worth €81k on the other. The net balance comes to €61k on the selling side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 7 share grants and 1 option exercise. In 2025 alone, the filings show 1 purchase and no sales.
The latest filing, published on 30 July 2025, reports an open-market purchase of €3,923 in Lexaria Bioscience Corp. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
13 of 13 declarations